Results 51 to 60 of about 423,899 (348)
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
Pulmonary Circulation, 2019 Pulmonary arterial hypertension is a severe disease for which diagnosis often is delayed. Matrix metalloproteinases have been suggested to play a role in vascular remodeling and pulmonary hypertension development. Our aim was therefore to investigate the
Mattias Arvidsson +3 more
doaj +1 more source
Right ventriculo–pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension
Pulmonary Circulation, 2020 Right ventricular function critically affects the prognosis of patients with pulmonary arterial hypertension. We aimed to analyze the prognostic value of right ventricular indices calculated using magnetic resonance imaging and right heart ...
Toshitaka Nakaya +8 more
doaj +1 more source
Transcription factors and potential therapeutic targets for pulmonary hypertension
Frontiers in Cell and Developmental Biology, 2023 Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial ...
Liu Yang +5 more
doaj +1 more source
Non-invasive assessment of pulmonary vascular resistance in pulmonary hypertension: Current knowledge and future direction [PDF]
, 2017 Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised. Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing diseases each with different treatments and prognoses.
Hills, G +4 more
core +2 more sources
Anticoagulation in pulmonary arterial hypertension: a decision analysis
Pulmonary Circulation, 2019 Systemic anticoagulation may be beneficial in pulmonary arterial hypertension, but there is no randomized clinical trial data to guide therapeutic decision making, and current guidelines do not account for patient preferences or quality of life. Decision
Arun Jose +2 more
doaj +1 more source
Cellular senescence impairs the reversibility of pulmonary arterial hypertension
Science Translational Medicine, 2020 The transition from reversible to irreversible pulmonary arterial hypertension involves vascular senescence and can be countered by senolysis. Reversing maladaptive remodeling Pathologic vascular remodeling of pulmonary arterial hypertension (PAH ...
D. E. van der Feen +19 more
semanticscholar +1 more source
Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension [PDF]
, 2018 Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models.
Alastalo +23 more
core +4 more sources
Pulmonary Circulation, 2022 Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability.
Mauricio Orozco‐Levi +11 more
doaj +1 more source
Sildenafil citrate therapy for pulmonary arterial hypertension.
New England Journal of Medicine, 2005 BACKGROUND Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate-mediated relaxation and growth inhibition of vascular smooth-muscle cells, including ...
N. Galiè +12 more
semanticscholar +1 more source
Circulation, 2020 Supplemental Digital Content is available in the text. Background: Angiotensin-converting enzyme 2 (ACE2) converts angiotensin II, a potent vasoconstrictor, to angiotensin-(1–7) and is also a membrane protein that enables coronavirus disease 2019 (COVID ...
Hui Shen +14 more
semanticscholar +1 more source